Intestinal Dysbiosis in Parkinson’s Disease: Mechanisms, Clinical Implications, and Therapeutic Perspectives (2015–2025)
Objective: This narrative review aims to consolidate research published from 2015 to 2025 regarding abnormalities in gut microbiota in patients with Parkinson’s disease, emphasizing potential…Investigating Phospho-α-Synuclein Pathology in Patient-Specific Microglia Integrated into Midbrain Organoids
Objective: This study aims to determine how patient-specific microglia influence phospho-α‑synuclein aggregation and contribute to disease-relevant phenotypes within human midbrain organoids. Background: Parkinson’s disease (PD)…LRRK2 G2019S Drives Lysosomal Lipid Remodeling and Inflammation in Human iPSC-Derived Microglia
Objective: The aim of this study is to elucidate disease-related metabolic and inflammatory pathways driven by LRRK2 G2019S in human iPSC-derived microglia. Background: Parkinson’s Disease…Macrophage Subtypes in Brainstem Catecholamine Regions in Healthy Ageing and Across Parkinson’s Disease.
Objective: To assess macrophages in the human brainstem in healthy ageing and during Parkinson’s disease (PD). Background: PD is the second most common neurodegenerative disorder…Neuronal DJ-1 regulates microglia activation via ADAM10-mediated CX3CL1 secretion
Objective: DJ-1, also known as Parkinson's disease protein 7 (PARK7), is a multifunctional protein that is important in regulating oxidative stress and neuroprotection. Background: The…Microglial Activation and Phenotype in Air Pollution Neurotoxicity: Implications for Parkinson’s Disease
Objective: To evaluate the impact of air pollution on microglial activation and phenotype and determine whether these changes persist following air quality improvement. Background: Epidemiological…Patient-specific Vascularized Midbrain Assembloids with Microglia show Altered Neuroinflammatory Phenotypes in Parkinson’s Disease
Objective: This study aims to develop patient-specific vascularized midbrain assembloids incorporating microglia to better model the neuroinflammatory environment of Parkinson’s disease (PD). By integrating vascular…Comparison of Microglial PET Imaging in Parkinson’s Disease, RBD, and Controls with a CSF1R and TSPO Ligand.
Objective: To compare regional binding patterns of microglial PET radioligands: [11C]DPA-713, a TSPO ligand, and [11C]CPPC1, a CSF1R ligand in people with Parkinson’s disease (PD).…The role of LRRK2 in regulating microglial activity in Parkinson’s disease
Objective: To investigate the effects of pathogenic LRRK2 mutations on lysosomal function and phagocytic activity of microglia. Background: The LRRK2 G2019S mutation is one of…Exploring the Therapeutic Potential of Microglial Modulation in Parkinson’s Disease: A Study on Structural Synaptic Plasticity
Objective: We aim to explore the role of glial cells in Parkinson's disease and assess whether modulating microgliafunction could offer therapeutic benefits. Specifically, we investigate…
- 1
- 2
- 3
- 4
- Next Page »